...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hybridoma and hybridomics >7A7 MAb: a new tool for the pre-clinical evaluation of EGFR-based therapies.
【24h】

7A7 MAb: a new tool for the pre-clinical evaluation of EGFR-based therapies.

机译：7A7 MAb：用于基于EGFR的疗法的临床前评估的新工具。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The epidermal growth factor receptor (EGFR) is highly expressed in many types of epithelial tumors. EGFR overexpression has been associated with an advanced stage of the disease, with resistance to standard therapies, and, for certain tumors, with poor patient prognosis. As a result, EGFR has been considered a meaningful target in anti-tumor strategies. Active and passive immunotherapies blocking EGFR and its ligands have been explored. But for successful pre-clinical evaluation of these approaches, well-established murine tumor models are not available and highly desirable. We described, for the first time, the generation and characterization of an anti-murine EGFR extracellular domain monoclonal antibody (7A7 MAb) (IgG1). 7A7 was generated by immunization of Balb/c mice with the recombinant extracellular domain of murine EGFR (rECD-mEGFR). 7A7 recognized an epitope present in the amino acidic core of the antigen and is cross-reactive with the human EGFR. Interestingly, this MAb was able to specifically bind EGFR at the cell surface, allowing the assessment of its differential expression in a panel of murine cells. Noteworthy, in a preliminary immunohistochemical study with 7A7 MAb, recognition of Balb/c mice skin sections and EGFR-positive tumors were observed. We concluded that 7A7 MAb is a valuable tool for EGFR-based therapeutic pre-clinical studies.
机译：表皮生长因子受体（EGFR）在许多类型的上皮肿瘤中高度表达。 EGFR的过表达与疾病的晚期，对标准疗法的抗性有关，对于某些肿瘤，患者的预后不良。结果，EGFR被认为是抗肿瘤策略中有意义的靶标。已经探索了阻断EGFR及其配体的主动和被动免疫疗法。但是，对于这些方法的成功的临床前评估，尚无成熟的鼠类肿瘤模型，因此非常需要。我们首次描述了抗鼠EGFR细胞外域单克隆抗体（7A7 MAb）（IgG1）的产生和表征。图7A7是通过用鼠EGFR的重组细胞外结构域（rECD-mEGFR）免疫Balb / c小鼠而产生的。 7A7识别抗原的氨基酸核心中存在的表位，并且与人EGFR交叉反应。有趣的是，该MAb能够在细胞表面特异性结合EGFR，从而可以评估其在一组鼠细胞中的差异表达。值得注意的是，在使用7A7 MAb进行的初步免疫组织化学研究中，观察到Balb / c小鼠皮肤切片和EGFR阳性肿瘤的识别。我们得出的结论是7A7 MAb是基于EGFR的临床前治疗研究的宝贵工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号